Active Shortage Injection Anti-Infective
Rifampin Injection · #17 of 35 active shortages by FDA posting duration
Brand: RIFAMPIN
FDA lists Rifampin Injection as Active Shortage (Mylan Institutional, a Viatris Company).
Availability on file: Available
Rifampin Injection: Active Shortage
Available 12 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Rifampin Injection
- Manufacturer
- Mylan Institutional, a Viatris Company
- Dosage Form
- Injection
- Presentation
- Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)
- Package NDC
- 67457-445-60
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Feb 17, 2021
- Last Updated
- Mar 18, 2026
- Therapeutic Category
- Anti-Infective
Row fields from the FDA Drug Shortages database via openFDA.
Full Drug Profile
rifampin
Side effects, interactions, warnings & more
Nearby, Other Rifampin Shortage Records
Rifampin Injection
Sanofi-Aventis U.S. LLC
Injection
Rifampin Injection
Fresenius Kabi USA, LLC
Injection
Rifampin Capsule
Epic Pharma, LLC
Capsule
Rifampin Capsule
Epic Pharma, LLC
Capsule
Rifampin Capsule
Epic Pharma, LLC
Capsule
Rifampin Capsule
Epic Pharma, LLC
Capsule